Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Does Esperion's Plan For A Statin-Intolerant Claim Have A Shot?

Executive Summary

Esperion says it is working with FDA to forge a new regulatory path for its cholesterol drug ETC-1002 in statin-intolerant patients – a population the agency has been very cautious about in the past.

Advertisement

Related Content

Esperion Says FDA On Board With Filing Strategy For Bempedoic Acid
FDA’s Zetia/Vytorin Rejection Leaves Cholesterol Drug Sponsors In Limbo
Amgen Racks Up Positive Phase III Data For Blincyto And Repatha
PCSK9 Inhibitors May Feel Effects Of FDA Judgment On IMPROVE-IT
PCSK9 Inhibitors May Feel Effects Of FDA Judgment On IMPROVE-IT
LDL Hypothesis Brings Out Skeptics, Supporters At FDA Panel
IMPROVE-IT Study: Negative Panel Review Leaves FDA With Tough Choice
Cholesterol Guidelines Look High And Low: Statin Market Extended At Both Ends
Branded Life After Lipitor: Pharma Targets Unmet Needs In Dyslipidemia

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057405

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel